Merck Serono Launches New Website

GENEVA, Switzerland, December 18 /PRNewswire/ --

- In-depth and Up-to-date Information on Merck Serono

- Latest News

- Up-to-Date List of Wordwide Job Opportunities

Merck Serono (NYSE: SRA), a division of Merck KGaA, announced today the
launch of its new website (http://www.merckserono.net). The fully redesigned
website provides in-depth and up-to-date information on the Merck Serono
division, in particular on its medical treatments, services and research &
development activities, along with the latest news about the division.

"The Merck Serono website is part of our commitment to open
and transparent communication with our various stakeholders," said François
Naef, Merck Serono's Head of Human Resources, Legal and Communications. "The
new website will provide anyone with an interest in Merck Serono the
opportunity to learn more about our division and its activities".

The Merck Serono website also provides a current list of
worldwide job opportunities at Merck Serono and allows candidates to apply
on-line.

The website is designed for ease of navigation and use so that
visitors can quickly access the information they are seeking. New websites
for Merck Serono's local affiliates will be launched throughout 2008.

About Merck Serono

Merck Serono, the new division for innovative small molecules and
biopharmaceuticals of Merck, was established following the acquisition of
Serono and the integration of its business with the former Merck Ethicals
Division. Headquartered in Geneva, Switzerland, Merck Serono discovers,
develops, produces and commercializes innovative products to help patients
with diseases with unmet needs. Our North American business operates in the
United States and Canada under EMD Serono.

Merck Serono has leading brands serving patients with cancer
(Erbitux(R)), multiple sclerosis (Rebif(R)), infertility (Gonal-f(R)),
metabolic and cardiometabolic disorders (Glucophage(R), Concor(R), Saizen(R),
Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D
investment of EUR 1bn, we are committed to growing our business in
specialist-focused therapeutic areas such as Neurodegenerative Diseases and
Oncology, as well as new therapeutic areas potentially arising out of our
research and development in Autoimmune and Inflammatory Diseases.

About Merck

Merck is a global pharmaceutical and chemical company with
sales of EUR 6.3 billion in 2006, a history that began in 1668, and a future
shaped by 30,962 employees in 61 countries. Its success is characterized by
innovations from entrepreneurial employees. Merck's operating activities come
under the umbrella of Merck KGaA, in which the Merck family holds an
approximately 70% interest and free shareholders own the remaining
approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated
and has been an independent company ever since.

For more information, please visit http://www.merckserono.net
or http://www.merck.de